Table 1. Plk inhibitor compounds.
Chemical structures of Plk1 inhibitors are shown along with their target and the phase/status of the trials discussed in the text. Further information regarding the trials and compound history may be found using the Clinical Trials Registry Number or reference provided.
| Compound | Structure | Target | Clinical Trial Phase | Clinical Trial Status | Ref. and NCT number |
|---|---|---|---|---|---|
| BI2536 |
|
ATP-binding domain | Phase II | Completed 2008 (primary) | (58, 59) NCT 00710710 |
| BI6727 (volasertib) |
|
ATP-binding domain | Phase III | Active, not recruiting | (63) NCT 01721876 |
| Tak960 |
|
ATP-binding domain | Phase I | Terminated 2013 | (73) NCT 01179399 |
| NMS-P937 |
|
ATP-binding domain | Phase I | Completed 2011 (primary) | (76, 77) NCT 01014429 |
| ON 01910.Na (rigosertib) |
|
Plk1 non-competitive and PI3K | Phase III | Completed 2015 | (80, 81) NCT 01360853 |
| GSK461364 |
|
ATP-binding domain | Phase I | Completed 2009 | (88, 90) NCT 00536835 |
| Poloxin |
|
Polo-box domain | None | N/A | (70, 71) |
| Poloxin-2 |
|
Polo-box domain | None | N/A | (72) |